OncoGenex Pharma (OGXI) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015
May 14, 2015 4:01 PM EDTConference call to be held on Thursday, May 14, 2015 at 4:30 p.m. Eastern Time
BOTHELL, Wash. and VANCOUVER, British Columbia, May 14, 2015 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced first quarter 2015 financial results.
Recent Developments and Anticipated Near-term Milestones
Custirsen
On April 27, 2015 OncoGenex announced it regained rights to custirsen, its investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights occurred in connection with the termination of the 2009... More